Home / Register for webinar: DILI Uncovered: how to mitigate hepatoxicity failure
Register for webinar: DILI Uncovered: how to mitigate hepatoxicity failure
Join us on 6th May 2026 at 9:00 AM EDT | 2:00 PM BST | 3:00 PM CEST for this live webinar.
Key Learnings:
-
Gain an overview of the key biological mechanisms known to contribute to drug-induced liver injury (DILI) and why understanding these mechanisms is critical when evaluating potential safety risks during drug development.
-
Understand the challenges associated with detecting DILI during preclinical development, including why some liabilities remain difficult to predict using traditional models.
-
Explore in vitro strategies that can help identify DILI risks earlier, supporting better decision-making and reducing the likelihood of late-stage safety failures.
-
Learn how emerging approaches and scientific perspectives are shaping the future of DILI assessment, and what this could mean for improving safety evaluation in drug discovery and development.
Who this webinar is designed for:
Biotech and small pharma in drug discovery
Teams looking to better understand and manage early safety risks.
Companies outsourcing in vitro toxicology assays
Organisations seeking partners for reliable in vitro toxicity testing.
Scientists responsible for in vitro tox strategies
Researchers designing or interpreting in vitro tox studies.
Meet the Speaker
Dr. Sanna-Mari Aatsinki – Head of Drug-Drug Interactions and In Vitro Toxicology, Admescope (a Symeres company)
Dr. Sanna-Mari Aatsinki has extensive research experience related to hepatic energy metabolism, gene regulation, mitochondrial function and toxicity having strong scientific background in various cell-based assays and mRNA analysis techniques. Sanna-Mari joined Admescope in 2011 and she is heading the metabolism and transporter mediated drug-drug interactions, in vitro toxicology and permeability research services team.
